Five-year survival rates for patients with advanced melanoma treated with pembrolizumab (Keytruda) are 34%, according to the longest follow-up study to date. Results from the international KEYNOTE-001 study involving 655 patients also show an estimated five-year overall survival rate of 41% for treatment-naïve patients with the PD-1 inhibitor. Published in the Annals of Oncology, the ...
Already a member?
Enter your email to keep reading.